Interestingly, BCR-ABL1 kinase domain mutations that were associated with TKI-resistance were also observed in 15% of CML patients with the BIM deletion polymorphism who experienced sub-optimal TKI responses [1]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.